EUVIMEDEUVIMED entdecken
Open Access

MRS Imaging as Complement to MRI in the Post‐treatment Follow‐up of Glial Brain Tumors

Pablo Moreno-Acosta, Gina Malaver, Cesar Rodriguez, Oscar Gamboa, Carla Singh, German D Diaz, Wafa Bouleftour, Trinidad González Padin, Josep Balart, Cristian Caicedo, Camilo Zubieta, Pedro Penagos und 1 weitere

Cancer Diagnosis & Prognosis · 01.09.2025 · 5 (5) · 625-633

DOI: 10.21873/cdp.10478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.09.2025. Verfasst von Pablo Moreno-Acosta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Grupo Investigación de Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: Central nervous system tumors have a very low incidence worldwide. However, they represent a significant cause of mortality and morbidity. Magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) and magnetic resonance spectroscopy imaging (MRSI) techniques provide metabolic information complementary to anatomical alterations. The aim of this study was to characterize different metabolic patterns and determine treatment outcomes in glial brain tumors. Patients and Methods: Forty-four previously treated patients participated in this prospective study, including 20 cases of low-grade (LG) and 24 high-grade (HG), gliomas. All patients underwent conventional MRI combined with MRS and MRSI using a 1.5 Tesla (T) magnet.

Results

Distinct metabolic profiles were observed via MRS and MRSI compared to normal brain tissue. Among the LG tumors, 10 remained stable with mean choline (Cho)/ N-Acetyl Aspartate (NAA) and NAA/creatine (Cr) ratios of 1.49 (p=0.036) and 0.92 (p=0.038), respectively, while the other 10 progressed to HG, with Cho/NAA and Cho/Cr ratios of 2.24 (p=0.026) and 4.48 (p=0.016). Among HG tumors, 17 remained stable with similar metabolic profiles, while seven showed progression. Gliosis was identified in 21 cases, characterized by a Cho/NAA ratio of 1.57 (p=0.028) and NAA/Cr ratio of 1.36 (p=0.026). Radiation necrosis was observed in 14 tumors, with significant spectroscopic changes including Cho/Cr ratios of 2.14 (p=0.02) and 1.9 (p=0.003), and NAA/Cr ratios of 1.28 (p=0.001) and 0.49 (p=0.001) across SV-MRS and MV-MRSI modalities. Tumor recurrence was detected in 20 cases based on MRSI metabolic maps.

Conclusion

MRS and MRSI provide valuable metabolic information that complements MRI in the post-treatment evaluation of glial brain tumors. These techniques enhance the detection of tumor recurrence, progression, and radiation necrosis, thereby supporting clinical decision-making and optimizing patient management.

Schlagwörter

Stichwörter der Autor:innen

Brain tumors of glial originmagnetic resonance spectroscopymagnetic resonance spectroscopy imaging

Autor:innen und Institutionen

  • Grupo Investigación de Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Grupo de Investigación en Radiobiología Clínica, Molecular y Celular, Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Imagenes Diagnósticas, Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Radioterapia, Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Inmugen Corporation, Bogotá, Colombia.
  • Department of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint Etienne Medicine University, Saint Etienne, France.

Zitieren

APA

Moreno-Acosta, P., Malaver, G., Rodriguez, C., Gamboa, O., Singh, C., Diaz, G. D., Bouleftour, W., Padin, T. G., Balart, J., Caicedo, C., Zubieta, C., Penagos, P., & Magné, N. (2025). MRS Imaging as Complement to MRI in the Post‐treatment Follow‐up of Glial Brain Tumors. Cancer Diagnosis & Prognosis, 5(5), 625-633. https://doi.org/10.21873/cdp.10478

Vancouver

Moreno-Acosta P, Malaver G, Rodriguez C, Gamboa O, Singh C, Diaz GD, et al. MRS Imaging as Complement to MRI in the Post‐treatment Follow‐up of Glial Brain Tumors. Cancer Diagnosis & Prognosis. 2025;5(5):625-633. doi:10.21873/cdp.10478

BibTeX
@article{MorenoAcosta2025,
  author = {Moreno-Acosta, Pablo and Malaver, Gina and Rodriguez, Cesar and Gamboa, Oscar and Singh, Carla and Diaz, German D and Bouleftour, Wafa and Padin, Trinidad González and Balart, Josep and Caicedo, Cristian and Zubieta, Camilo and Penagos, Pedro and Magné, Nicolas},
  title = {MRS Imaging as Complement to MRI in the Post‐treatment Follow‐up of Glial Brain Tumors},
  journal = {Cancer Diagnosis & Prognosis},
  year = {2025},
  volume = {5},
  number = {5},
  pages = {625--633},
  doi = {10.21873/cdp.10478}
}
Kostenlos starten →